HRT Financial’s Pacira BioSciences PCRX Stock Holding History

HRT Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Buy	65,927 +47,543	+259%	+$1.12M	﹤0.01%	1845
2026 Q1	$415K	Sell	18,384 -98,011	-84%	-$2.18M	﹤0.01%	2662
2025 Q4	$3.01M	Buy	116,395 +7,936	+7%	+$189K	0.01%	1038
2025 Q3	$2.79M	Buy	+108,459	New	+$2.66M	0.01%	963
2025 Q2	–	Sell	-176,688	Closed	-$4.39M	–	3316
2025 Q1	$4.39M	Sell	176,688 -3,213	-2%	-$76.9K	0.03%	478
2024 Q4	$3.39M	Buy	+179,901	New	+$3.16M	0.02%	539
2023 Q2	–	Sell	-6,645	Closed	-$271K	–	3058
2023 Q1	$271K	Sell	6,645 -153,077	-96%	-$6.09M	﹤0.01%	1773
2022 Q4	$6.17M	Buy	159,722 +137,685	+625%	+$6.7M	0.09%	210
2022 Q3	$1.17M	Buy	+22,037	New	+$1.23M	0.01%	821
2021 Q4	–	Sell	-19,157	Closed	-$1.07M	–	3855
2021 Q3	$1.07M	Sell	19,157 -35,147	-65%	-$2.03M	0.01%	1204
2021 Q2	$3.29M	Buy	+54,304	New	+$3.44M	0.03%	417
2019 Q4	–	Sell	-7,938	Closed	-$302K	–	1519
2019 Q3	$302K	Buy	+7,938	New	+$317K	0.01%	940
2019 Q1	–	Sell	-7,866	Closed	-$338K	–	718
2018 Q4	$338K	Buy	+7,866	New	+$367K	0.05%	315

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's PCRX Position: Q2 2026 in Review

HRT Financial increased its Pacira BioSciences (PCRX) stake by 259% in Q2 2026, buying an estimated $1.12M and bringing the position to 65,927 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

HRT Financial first reported a position in PCRX in Q4 2018 and has held it in 13 quarters since. The position peaked at $6.17M in Q4 2022. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

HRT Financial held 65,927 shares of Pacira BioSciences worth $1.67M as of Q2 2026.
HRT Financial bought 47,543 Pacira BioSciences shares in Q2 2026, an estimated $1.12M.
Pacira BioSciences made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #1845 holding.
HRT Financial first reported a position in Pacira BioSciences in Q4 2018 and has held it in 13 quarters since.
HRT Financial's Pacira BioSciences position peaked at $6.17M in Q4 2022.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.